undamentalytics Newsletter
Sign in

Mimedx Group, Inc. income statement

In fiscal 2025, Mimedx Group, Inc. reported revenue of $419m, up 20.0% on the year before, operating income of $63.9m (a 15.3% margin) and net income of $48.6m, or $0.32 per diluted share. Every line below comes from the company's 10-K and 10-Q filings; column headings link to the filing.

Income statement

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2010Dec 20102011Dec 20112016Dec 20162017Dec 20172018Dec 20182019Dec 20192020Dec 20202021Dec 20212022Dec 20222023Dec 20232024Dec 20242025Dec 2025LTMSept 2026
Revenue18222321359299248242268321349419304
Cost of revenue——3135364339404855607369
Gross profit—4191286323256209202220267289346235
Research and development331418161112101313121514
Selling, general and administrative710173220259198181195209211225266244
Operating income−11−10146−4−21−45−7−15375964−25
Interest expense100—————5742—
Net interest income——−0−01−5−8−5−5−6———
Income before tax−11−10145−3−26−62−12−20315766−22
Income tax000−2027−0−1200−371518−3
Net income−11−10065−30−26−49−10−30584249−19
Diluted EPS−$0.19−$0.14$0.00$0.56−$0.28−$0.24−$0.77−$0.15−$0.33$0.37$0.28$0.32−$0.13
Diluted shares (average)—72m113m116m106m107m108m110m113m146m149m150m148m
EBITDA−10−94502−15−40−3−11416579−11

EBITDA is operating income plus depreciation and amortisation. EPS and share counts are restated for stock splits. A dash means the company did not report the line for that period; expense lines are shown as reported, so they need not add up to the totals when a company reports other items between them.

Compare with peers

Head to head: MDXG vs ORGOMDXG vs UFPTMDXG vs OSUR

More: Health Care Supplies stocks compared, Health Care sector, rankings of US companies

Figures from Mimedx Group, Inc.'s SEC filings (10-K and 10-Q), retrieved October 29, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Mimedx Group, Inc.